ARTES Biotechnology and Basic Pharma are almost there! The companies are nearing completion of their joint project with the production of recombinant Human Serum Albumin (rHSA) and the first vials are expected to be available this summer. ARTES, a leading company that specialized in developing and transferring recombinant cell lines and protein production processes from […]
continue reading
ARTES Biotechnology announce expansion of the management board
ARTES Biotechnology GmbH announced today that Volker Jenzelewski reinforces the executive board of ARTES as Managing Director beginning of the year. He will manage the company in close cooperation with Dr. Michael Piontek, Managing Director and founder of ARTES Biotechnology and with Dr. Melanie Piontek, Business Development Director. Volker Jenzelewski started his career at Rhein […]
continue readingARTES Biotechnology and Basic Pharma join in a strategic Collaboration and Co-Marketing Partnership for Pharmaceutical Recombinant Protein Production
company focusing on niche pharmaceutical products, are proud to announce a strategic collaboration aimed at advancing pharmaceutical innovation. Under the terms of this collaboration agreement, ARTES Biotechnology and Basic Pharma will harness their respective expertise, cutting-edge technologies, and marketing strategies for the development and production of nonGMP recombinant proteins in a first step. This initial […]
continue readingARTES 20th Year Anniversary – a short overview
In 2002 at May 10th Michael Piontek founded ARTES as a one-man operation executing and taking care of two license deals as part of a severance agreement. He was absolute sure that this will be an interim solution only while looking for new job opportunities. Nevertheless, as always, things took an unexpected course. About half […]
continue readingCellumed and ARTES Sign Development and License Agreement
Today, Cellumed Co. Ltd., listed stock market company and Germany based ARTES Biotechnology GmbH announce the execution of a Development and License Agreement aiming at the generation of microbial production cell lines, processes and documentation for the cGMP manufacturing of two enzymes required in the manufacturing process of mRNA vaccines. Under this agreement, ARTES shall […]
continue reading